Drugs / F0002-ADC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03894150 | Apr 2019 → Jul 2020 | refractory hematologic cancer | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F0002-ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03894150 ↗ |